Treace Medical Concepts, specializing in foot and ankle surgery devices, demonstrated continued top-line growth reaching $213 million in fiscal 2025, up 1.6% year-over-year. Despite expanding revenue, the company remains unprofitable with a net loss of $59 million and negative operating cash flow, reflecting significant investment and commercialization costs. Treace maintains a strong liquidity position supported by sizable cash reserves and access to a $125 million term loan facility, though debt covenants require careful financial management. The company's moat relies heavily on patent-protected technologies actively defended in litigation against competitors, representing both a strategic asset and potential risk factor going forward.